Oil prices hold sharp losses with focus on secondary India tariffs
TORONTO - Hyperfine, Inc. (NASDAQ:HYPR), a medical technology company with a market capitalization of $84 million and strong financial health according to InvestingPro metrics, reported promising interim results from its CARE PMR study showing that its portable Swoop MRI system achieved 100% sensitivity in detecting ARIA-E, a side effect in patients receiving amyloid-targeting Alzheimer’s therapies.
The study, presented at the 2025 Alzheimer’s Association International Conference in Toronto, included 31 Alzheimer’s patients undergoing Lecanemab therapy who were scanned with both the Swoop system and conventional high-field MRI within a one-week period.
ARIA-E, characterized by cerebral edema, is a condition that requires monitoring in patients receiving FDA-approved amyloid-targeting therapies. Current protocols require multiple MRI scans throughout treatment, which can be costly and logistically challenging.
Dr. Tammie Benzinger, principal investigator from Washington University School of Medicine in St. Louis, noted, "This research could help alleviate the burden on families and facilities and improve overall access to care."
The portable, ultra-low-field Swoop system could potentially serve as a triage tool at points of care such as neurology offices and infusion clinics, though researchers indicated high-field MRI may still be necessary for comprehensive evaluation in some cases. The company’s stock has shown strong momentum, with an 11.47% return over the past week, while maintaining a healthy balance sheet with more cash than debt and a current ratio of 6.07.
The CARE PMR study is funded by the Alzheimer’s Association and the American Society of Neuroradiology to assess the clinical utility of using the Swoop system to detect amyloid-related imaging abnormalities in Alzheimer’s patients.
Hyperfine’s Swoop system is FDA-cleared for brain imaging of patients of all ages. The company aims to expand access to diagnostic imaging by providing portable MRI technology at the point of care.
This article is based on a press release statement from Hyperfine, Inc. With the company’s next earnings report due on August 7, 2025, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, which transform complex financial data into actionable intelligence for smarter investment decisions.
In other recent news, Hyperfine, Inc. reported its first-quarter 2025 earnings, revealing a significant shortfall in both earnings per share and revenue forecasts. The company posted a net loss of $9.4 million, or $0.12 per share, which was slightly below the expected EPS of -$0.1167. Revenue was $2.1 million, missing the anticipated $2.89 million. Despite these financial setbacks, Hyperfine has been active in launching new products and updates. The company began rolling out its FDA-cleared Optive AI™ software to enhance its Swoop® portable MRI systems. This software aims to improve image quality by refining noise cancellation and other imaging processes. Additionally, Hyperfine announced the first commercial sales of its next-generation Swoop systems to two hospitals in the northeastern United States. These developments follow the FDA clearance of its latest portable MRI scanner, which promises improved resolution and faster acquisition times.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.